Wednesday, 24 December 2014

Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity

Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity (Novo Nordisk)


Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy

Our results suggest that not only proteinuria but also tubulointerstitial lesions should be assessed to predict rapid eGFR decline in patients with type 2 diabetes who have overt proteinuria and biopsy-proven DN (Diabetes/Metabolism Research and Reviews)

No comments:

Post a Comment